subscribeSubscribe
Areteia Therapeutics Announces Additional $75MM in Series A Financing

Areteia Therapeutics Announces Additional $75MM in Series A Financing
BUSINESSWIRE
13 Feb 2024
Share Share
Areteia Therapeutics Announces Publication of PII Data of Oral Dexpramipexole

Areteia Therapeutics Announces Publication of PII Data of Oral Dexpramipexole
BUSINESSWIRE
03 Aug 2023
Share Share
Areteia Announces Start of Phase III Trials of Oral Dexpramipexole

Areteia Announces Start of Phase III Trials of Oral Dexpramipexole
BUSINESSWIRE
09 Mar 2023
Share Share
Bain leads $350M bet on oral asthma startup to fund phase 3

Bain leads $350M bet on oral asthma startup to fund phase 3
Nick Paul Taylor FIERCEBIOTECH
12 Jul 2022
Share Share
Knopp Bio Presents New Phase 2 Data at AAAAI 2022 on Oral Dexpramipexole

Knopp Bio Presents New Phase 2 Data at AAAAI 2022 on Oral Dexpramipexole
BUSINESSWIRE
28 Feb 2022
Share Share
Knopp Biosciences Announces Positive Results from the Phase 2 EXHALE Trial

Knopp Biosciences Announces Positive Results from the Phase 2 EXHALE Trial
BUSINESSWIRE
08 Sep 2021
Share Share
Knopp Biosciences Presents New Phase 2 Data at ERS 2021

Knopp Biosciences Presents New Phase 2 Data at ERS 2021
BUSINESSWIRE
07 Sep 2021
Share Share
Knopp meldet positive Top-Line-Ergebnisse aus der Ph-2-Studie EXHALE

Knopp meldet positive Top-Line-Ergebnisse aus der Ph-2-Studie EXHALE
BUSINESSWIRE
14 Jan 2021
Share Share
Knopp Biosciences to begin Trial of Oral Dexpramipexole in Eosinophilic Asthma

Knopp Biosciences to begin Trial of Oral Dexpramipexole in Eosinophilic Asthma
GLOBENEWSWIRE
16 Sep 2020
Share Share
Can Biogen rebound in ALS? Maybe so, new antisense data suggest

Can Biogen rebound in ALS? Maybe so, new antisense data suggest
Amirah Al Idrus FIERCE BIOTECH
09 Jul 2020
Share Share